RAPID IMPROVEMENT IN PULMONARY HYPERTENSION RELATED WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA BY ILOPROST INHALATION IN A POSTPARTUM PATIENT: A CASE REPORT
Shengyu Hao,Yaxiaerjiang Muhetaer,Xin Zheng,Nianwei Zhou,Ming Zhong
DOI: https://doi.org/10.1016/j.chest.2023.07.3902
IF: 9.6
2023-01-01
Chest
Abstract:SESSION TITLE: Pulmonary Vascular Disease Global Case Report Posters 1 SESSION TYPE: Global Case Reports PRESENTED ON: 10/10/2023 12:00 pm - 12:45 pm INTRODUCTION: Postpartum pulmonary arterial hypertension (PAH) complicated with hereditary hemorrhagic telangiectasia (HHT) is a rare condition1. To the best of our knowledge, there are no reports to date that have investigated whether pulmonary vasodilators improve hemodynamics in postpartum patients with HHT-PAH. CASE PRESENTATION: A 28-year-old postpartum patient was admitted to our hospital due to dyspnea. In the 10 days before admission, she had a spontaneous vaginal delivery of a health boy. Then she began to experience significant dyspnea. Cyanosis was noted on her lips and telangiectasias were seen on her fingertips. Arterial blood gases analysis revealed type I respiratory failure (PaO2/FiO2 ratio (P/F): 135mmHg, PaO2: 54mmHg, PaCO2: 27mmHg, PH: 7.4). Her blood count was normal but with increased hemoglobin (151g/L). Liver, kidney and cardiac indicators revealed slightly decreased albumin (37g/L), and increased LDH (276U/L), ALT (106U/L), uric acid (458umol/L) and NT-proBNP (141pg/ml). Immunological markers were normal. Echocardiography revealed an increased pulmonary artery systolic pressure (PASP: 51 mmHg). CTA demonstrated multiple bilateral pulmonary arteriovenous malformations (AVMs). Genetic testing revealed an ACVRL1 mutation (chr12:52308295, NM_000020.3, c.698C>G, (p.S233W)). Sublingual microcirculation testing did not reveal significant abnormalities. She had a full-term birth of a girl 3 years ago, with the previous pregnancy being uneventful except for recurrent epistaxis. Her mother also had recurrent epistaxis throughout her two pregnancies. Within the first 7 days after admission, she received diuretic (hydrochlorothiazide, triamterene) and anticoagulant (low molecular weight heparin calcium). However, her dyspnea continued to worsen with decreased P/F (from 135 to 82 mmHg), increased PASP (from 51 to 80 mmHg) and elevated NT-proBNP (from 162 to 461 pg/ml). Sidenafil and macitentan were added for 4 days, followed by 24-hour inhaled nitric oxide. However, significant improvement was not observed. The patient was then treated with Ventavos, an iloprost solution for inhalation, and an immediate improvement in her symptom and indicators was observed. She was discharged on the 27th day with modified symptoms and indicators (P/F: 297mmHg, NT-proBNP: 123pg/ml and PASP: 50mmHg). The patient declined to continue medication after her discharge. On the 100 days of telephone follow-up, she was still alive with a resting SpO2 of 90-92% measured by finger oximeter. DISCUSSION: PAH is a rare but severe complication of HHT, usually leading to a worse outcome than PAH alone. ACVRL1 mutations have been recognized as a combination of HHT and PAH. Importantly, PAH patients with an ACVRL1 mutation are diagnosed at a younger age and have worse prognosis with a poor response to pulmonary vasodilation drugs2. While a systematic review showed that oral or intravenous prostanoids improved the hemodynamics and survival in 25 HHT-PAH with ACVRL1 mutation subjects3. CONCLUSIONS: We present a case report of PAH and HHT occurring in a postpartum woman as a result of an ACVRL1 mutation. This case highlights the difficulty in treating PAH in HHT patients, such as in this case. The changes of indicators suggested that except for iloprost inhalation, the other treatments seemed to have limited effect. REFERENCE #1: Bofarid S, Hosman AE, Mager JJ, Snijder RJ, Post MC. Pulmonary Vascular Complications in Hereditary Hemorrhagic Telangiectasia and the Underlying Pathophysiology. Int J Mol Sci. 2021;22(7). REFERENCE #2: Lyle MA, Fenstad ER, McGoon MD, et al. Pulmonary Hypertension in Hereditary Hemorrhagic Telangiectasia. Chest. 2016;149(2):362-371. REFERENCE #3: Abston E, Hon S, Rodriguez-Lopez J, et al. Treatment of pulmonary hypertension in patients with Hereditary Hemorrhagic Telangiectasia - A case series and systematic review. Pulm Pharmacol Ther. 2021;68:102033. DISCLOSURES: No relevant relationships by Shengyu Hao No relevant relationships by Yaxiaerjiang Muhetaer No relevant relationships by Xin Zheng No relevant relationships by Ming Zhong No relevant relationships by Nianwei Zhou